Drug intelligence / Profile preview

Carliprazine

Development stage: Unknown
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral

Overview

Carliprazine (KH110) is a novel small-molecule antipsychotic developed by Chengdu Kanghong Pharmaceutical Group for the treatment of schizophrenia. It acts as a partial agonist at the dopamine D3 and D2 receptors, with a notably high affinity for the D3 subtype, and also functions as a partial agonist at the serotonin 5-HT1A receptor. This pharmacological profile is intended to manage the positive, negative, and cognitive symptoms of schizophrenia while potentially minimizing side effects such as weight gain and extrapyramidal symptoms. The drug is currently in Phase 3 clinical development in China, where it is being evaluated in a non-inferiority study compared to aripiprazole in patients with acute schizophrenia.

Other names: Carliprazine hydrochlorideHydrochloride carliprazine

Targets

ADRA1A (α1A)HTR2A (Serotonin receptor 5-HT2A)DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on Carliprazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carliprazine.

Explore the full profile